Annual report pursuant to Section 13 and 15(d)

Consolidated Financial Statements Details - Intangible Assets, Net (Details)

v3.24.0.1
Consolidated Financial Statements Details - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Intangible assets, net      
Cost $ 15,247 $ 15,247 $ 15,247
Accumulated Amortization 994 994 97
Impairment Charge   14,253  
Net Carrying Value     15,150
Ebopiprant IP      
Intangible assets, net      
Cost 15,247 15,247 15,247
Accumulated Amortization 994 994 97
Impairment Charge   $ 14,253  
Net Carrying Value     15,150
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income   Impairment charges (Note 4, Note 5)  
Ebopiprant IP | ObsEva, Organon | License Agreement      
Intangible assets, net      
Impairment Charge $ 14,200 $ 14,200 $ 0
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income Impairment charges (Note 4, Note 5) Impairment charges (Note 4, Note 5)